These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8714617)

  • 21. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
    Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 23. Cladribine: not just another purine analogue?
    Spurgeon S; Yu M; Phillips JD; Epner EM
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1169-81. PubMed ID: 19604118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunosuppressive therapy].
    Purice S
    Stud Cercet Med Interna; 1973; 14(3):209-16. PubMed ID: 4574134
    [No Abstract]   [Full Text] [Related]  

  • 25. Rituximab in autoimmune pancytopenia: a case report and review of literature.
    Reale LD; Besa EC
    Ann Hematol; 2007 Dec; 86(12):913-6. PubMed ID: 17541587
    [No Abstract]   [Full Text] [Related]  

  • 26. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
    Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients.
    Grieb P; Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):323-7. PubMed ID: 8744654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous stem cell transplantation in autoimmune diseases.
    Passweg J; Tyndall A
    Semin Hematol; 2007 Oct; 44(4):278-85. PubMed ID: 17961728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O
    Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multiple sclerosis: from immunopathogenesis to disease management].
    Nervenarzt; 1996 Dec; 67(12 Suppl Von Der Im):1-8. PubMed ID: 9403091
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunosuppressive therapy].
    Schumacher K; Gross R
    Internist (Berl); 1984 Jan; 25(1):51-9. PubMed ID: 6370894
    [No Abstract]   [Full Text] [Related]  

  • 34. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological examination of the lacrimal gland after experimental administration of Cladribine.
    Kwietniewska M; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):526-30. PubMed ID: 12898890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunopathogenesis of multiple sclerosis: implications for treatment.
    Waldron-Lynch F; Hennessy MJ
    Ir Med J; 2004 Jan; 97(1):5-6. PubMed ID: 15055909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.